687 692
References
[1]
Antonarakis ES, Lu C, Wang H, et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med 2014;371:1028–38.
[2]
Mateo J, Carreira S, Sandhu S, et al. DNA-repair defects and olaparib in metastatic prostate cancer. N Engl J Med 2015;373:1697–708.
[3]
Crawford ED, Ventii K, Shore ND. New biomarkers in prostate cancer. Oncology (Williston Park) 2014;28:135–42.
[4]
Antonarakis ES, Lu C, Luber B, et al. Androgen receptor splice variant 7 and efficacy of taxane chemotherapy in patients with metastatic castration-resistant prostate cancer. JAMA Oncol 2015;1:582–91.[5]
Dehm SM, Tindall DJ. Alternatively spliced androgen receptor var- iants. Endocr Relat Cancer 2011;18:R183–96.[6]
Hu R, Dunn TA, Wei S, et al. Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone- refractory prostate cancer. Cancer Res 2009;69:16–22.[7]
Welti J, Rodrigues DN, Sharp A, et al. Analytical validation and clinical qualification of a new immunohistochemical assay for androgen receptor splice variant-7 protein expression in metastatic castration-resistant prostate cancer. Eur Urol 2016;70:599–608.
[8]
Onstenk W, Sieuwerts AM, Kraan J, et al. Efficacy of cabazitaxel in castration-resistant prostate cancer is independent of the presence of AR-V7 in circulating tumor cells. Eur Urol 2015;68:939–45.
[9]
Takeuchi T, Okuno Y, Hattori-Kato M, Zaitsu M, Mikami K. Detection of AR-V7 mRNA in whole blood may not predict the effectiveness of novel endocrine drugs for castration-resistant prostate cancer. Res Rep Urol 2016;8:21–5.[10]
Hessvik NP, Phuyal S, Brech A, Sandvig K, Llorente A. Profiling of microRNAs in exosomes released from PC-3 prostate cancer cells. Biochim Biophys Acta 2012;1819:1154–63.[11]
Junker K, Heinzelmann J, Beckham C, Ochiya T, Jenster G. Extracel- lular vesicles and their role in urologic malignancies. Eur Urol 2016;70:323–31.
[12]
Cai X, Janku F, Zhan Q, Fan JB. Accessing genetic information with liquid biopsies. Trends Genet 2015;31:564–75.
[13]
Gold B, Cankovic M, Furtado LV, Meier F, Gocke CD. Do circulating tumor cells, exosomes, and circulating tumor nucleic acids have clinical utility?. A report of the association for molecular pathology. J Mol Diagn 2015;17:209–24.
[14]
Kalluri R. The biology and function of exosomes in cancer. J Clin Invest 2016;126:1208–15.[15]
Wicha MS, Hayes DF. Circulating tumor cells: not all detected cells are bad and not all bad cells are detected. J Clin Oncol 2011;29: 1508–11.[16]
Li Y, Alsagabi M, Fan D, Bova GS, Tewfik AH, Dehm SM. Intragenic rearrangement and altered RNA splicing of the androgen receptor in a cell-based model of prostate cancer progression. Cancer Res 2011;71:2108–17.[17]
Lu C, Luo J. Decoding the androgen receptor splice variants. Transl Androl Urol 2013;2:178–86.[18]
Scher HI, Lu D, Schreiber NA, et al. Association of AR-V7 on circu- lating tumor cells as a treatment-specific biomarker with outcomes and survival in castration-resistant prostate cancer. JAMA Oncol 2016;2:1441–9.
E U R O P E A N U R O L O G Y 7 1 ( 2 0 1 7 ) 6 8 0 – 6 8 7
687